September 25, 2024

Kiora Pharmaceuticals to Participate in Upcoming Investor Conferences

Encinitas, California--(Newsfile Corp. - September 25, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) (KPRX) ("Kiora" or the "Company"), will participate in the following investor conferences. The presentations will be accessible live and on-demand for 90 days from our IR homepage (ir.kiorapharma.com).

Lytham Partners Fall 2024 Investor Conference.

Monday, October 1, 2024 at 10:15 am EDT
Presenter: Melissa Tosca, Chief Financial Officer
Click here to register and view
To arrange a meeting with management, please email 1×1@lythampartners.com

Maxim Virtual Healthcare Conference | Ophthalmology Panel

Tuesday, October 15, 2024 at 11:00 am EDT
Presenter: Brian M. Strem, Ph.D., Chief Executive Officer
Click here to sign up (account creation required), register and view

LD Micro Conference

Tuesday, October 29 at 4:00 pm EDT
Presenter: Melissa Tosca, Chief Financial Officer
Click here to register and view

About Kiora Pharmaceuticals
Kiora Pharmaceuticals is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. KIO-301 is being developed for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.

In addition to news releases and SEC filings, we expect to post information on our website (www.kiorapharma.com) and social media accounts that could be relevant to investors. We encourage investors to follow us on Twitter and LinkedIn as well as to visit our website and/or subscribe to email alerts.

Contacts:
Investors
investors@kiorapharma.com



To view the source version of this press release, please visit
https://www.newsfilecorp.com/release/224520

SOURCE Kiora Pharmaceuticals, Inc.